Liquid Biopsy Components in Neurological Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (30 January 2024) | Viewed by 5122

Special Issue Editor


E-Mail Website
Guest Editor
Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia, Vall d'Hebron University Hospital, Barcelona, Spain
Interests: neurological diseases with main focus on multiple sclerosis; liquid biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the last decade, liquid biopsy is gaining attention in an area of neurological diseases. The liquid biopsy is performed by extracting and analysis of non-solid biological tissues, i.e. serum, plasma, tear, and saliva, without the need to undergo the invasive procedure. A liquid biopsy can be used for screening several components such as extracellular vesicles (EVs) (exosomes, microvesicles, and apoptotic bodies), cell-free DNA (cfDNA), microRNA (miRNA), transfer RNA (t-RNA), circulating tumor DNA (ct-RNA), circulating tumor cells (CTCs) derived from body fluids. Recent advancements in this field, including the use of new technologies, the development and standardization of new methods, have helped to overcome some of the technical issues related with liquid biopsy. This edition’s primary focus is to address key questions regarding role of different liquid components, and the identification of potential biomarkers and therapeutic targets in complex neurological conditions including Alzheimer’s disease, amyotrophic lateral sclerosis, CNS tumors, epilepsy, multiple sclerosis, neuroinfectious disease and Parkinson’s disease.

Dr. Sunny Malhotra Sareen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liquid biopsy
  • microRNA
  • exosomes
  • cfDNA
  • neurological diseases

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 5551 KiB  
Article
Liquid Biopsy in Alzheimer’s Disease Patients Reveals Epigenetic Changes in the PRLHR Gene
by Mónica Macías, Blanca Acha, Jon Corroza, Amaya Urdánoz-Casado, Miren Roldan, Maitane Robles, Javier Sánchez-Ruiz de Gordoa, María Elena Erro, Ivonne Jericó, Idoia Blanco-Luquin and Maite Mendioroz
Cells 2023, 12(23), 2679; https://0-doi-org.brum.beds.ac.uk/10.3390/cells12232679 - 22 Nov 2023
Cited by 3 | Viewed by 1182
Abstract
In recent years, new DNA methylation variants have been reported in genes biologically relevant to Alzheimer’s disease (AD) in human brain tissue. However, this AD-specific epigenetic information remains brain-locked and unreachable during patients’ lifetimes. In a previous methylome performed in the hippocampus of [...] Read more.
In recent years, new DNA methylation variants have been reported in genes biologically relevant to Alzheimer’s disease (AD) in human brain tissue. However, this AD-specific epigenetic information remains brain-locked and unreachable during patients’ lifetimes. In a previous methylome performed in the hippocampus of 26 AD patients and 12 controls, we found higher methylation levels in AD patients in the promoter region of PRLHR, a gene involved in energy balance regulation. Our aim was to further characterize PRLHR’s role in AD and to evaluate if the liquid biopsy technique would provide life access to this brain information in a non-invasive way. First, we extended the methylation mapping of PRLHR and validated previous methylome results via bisulfite cloning sequencing. Next, we observed a positive correlation between PRLHR methylation levels and AD-related neuropathological changes and a decreased expression of PRLHR in AD hippocampus. Then, we managed to replicate the hippocampal methylation differences in plasma cfDNA from an additional cohort of 35 AD patients and 35 controls. The isolation of cfDNA from the plasma of AD patients may constitute a source of potential epigenetic biomarkers to aid AD clinical management. Full article
(This article belongs to the Special Issue Liquid Biopsy Components in Neurological Diseases)
Show Figures

Graphical abstract

Review

Jump to: Research

16 pages, 960 KiB  
Review
Liquid Biopsy in Neurological Diseases
by Sunny Malhotra, Mari Carmen Martín Miras, Agustín Pappolla, Xavier Montalban and Manuel Comabella
Cells 2023, 12(14), 1911; https://0-doi-org.brum.beds.ac.uk/10.3390/cells12141911 - 22 Jul 2023
Cited by 8 | Viewed by 3327
Abstract
The most recent and non-invasive approach for studying early-stage biomarkers is liquid biopsy. This implies the extraction and analysis of non-solid biological tissues (serum, plasma, saliva, urine, and cerebrospinal fluid) without undergoing invasive procedures to determine disease prognosis. Liquid biopsy can be used [...] Read more.
The most recent and non-invasive approach for studying early-stage biomarkers is liquid biopsy. This implies the extraction and analysis of non-solid biological tissues (serum, plasma, saliva, urine, and cerebrospinal fluid) without undergoing invasive procedures to determine disease prognosis. Liquid biopsy can be used for the screening of several components, such as extracellular vesicles, microRNAs, cell-free DNA, cell-free mitochondrial and nuclear DNA, circulating tumour cells, circulating tumour DNA, transfer RNA, and circular DNA or RNA derived from body fluids. Its application includes early disease diagnosis, the surveillance of disease activity, and treatment response monitoring, with growing evidence for validating this methodology in cancer, liver disease, and central nervous system (CNS) disorders. This review will provide an overview of mentioned liquid biopsy components, which could serve as valuable biomarkers for the evaluation of complex neurological conditions, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, stroke, traumatic brain injury, CNS tumours, and neuroinfectious diseases. Furthermore, this review highlights the future directions and potential limitations associated with liquid biopsy. Full article
(This article belongs to the Special Issue Liquid Biopsy Components in Neurological Diseases)
Show Figures

Figure 1

Back to TopTop